Special Groups




Head and neck cancer is a unique cause of dysphagia. Altered swallow function can be secondary to the mechanical effects of a tumor invading normal anatomy needed for deglutition, or as a direct sequela of cancer treatment (surgery and/or radiation ± chemotherapy). This article outlines the incidence of head and neck cancer, effects of anatomic changes associated with common surgical intervention, and the consequences of treatment-induced dysphagia. Assessment and rehabilitation techniques applicable for this population are discussed.


Key points








  • Persistent human papillomavirus (HPV) infection of the oral cavity may lead to genetic damage and altered immune function, promoting progression to cancer; specifically squamous cell carcinoma of the tonsils and base of tongue.



  • Radiation and chemotherapy can have adverse effects on overall function and quality of life.



  • Surgery can have devastating effects on swallow functioning, but results are somewhat predictable and dependent on the location of resection and clinical T stage.

































BOT Base of tongue
CRT Chemotherapy
HNC Head and neck cancer
HPV Human papillomavirus
IMRT Intensity-modulated radiotherapy
MDADI MD Anderson dysphagia inventory
TL Total laryngectomy
XRT Radiation therapy


Abbreviations: Head and Neck Cancer




Introduction


The incidence of head and neck cancer (HNC) has increased significantly over the past decade. According to the American Cancer Society, in 2012 an estimated 92,860 new cancer cases involved the oral cavity and pharynx, tongue, mouth, pharynx, other oral cavity, and larynx ( Fig. 1 ).




Fig. 1


Estimated new number of head & neck cancer cases by location in 2012 versus 2005 according to the American Cancer Society.

( Data from American Cancer Society. Cancer Facts & Figures 2012. Atlanta (GA): American Cancer Society; 2012. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf .)


The steady increase in incidence rates of oropharyngeal cancer over the past several decades has been attributed to the growing number of human papillomavirus (HPV)–related cancers. More than 90% of HPV-positive oropharyngeal cancers are associated with 2 oncogenic high-risk HPV types: HPV 16 and HPV 18. Subtype HPV 16 has been associated with 85% to 90% of all HPV-positive oropharyngeal cancers. Persistent HPV infection of the oral cavity may lead to genetic damage and altered immune function, promoting progression to cancer; specifically squamous cell carcinoma of the tonsil and base of tongue.


HPV status has been strongly associated with therapeutic response and overall survival in patients with oropharyngeal cancer. In general, survival rates for HPV-related oropharyngeal cancer are higher than those for HPV-unrelated oropharyngeal cancers, with 2-year survival rates ranging from 80% to 95% versus 50% to 65%, respectively. However, treatment for HPV-related and HPV-unrelated oropharyngeal cancers are currently commensurate. To date, little research has been conducted to determine if functional outcomes, including swallowing physiology, are similar among these heterogeneous groups.


Surgery, chemoradiotherapy or a combination of treatment can alter both the anatomy and tissue characteristics of those structures and muscles involved in swallowing. Radiotherapy can affect muscles, nerves, and the vascular system. Injury to the neuromuscular junctures and radiation-induced neuropathy can result in impairment in nerve conduction, muscle fiber atrophy, necrosis, and impairment in muscle contraction with an increase in connective tissue. Vascular changes following irradiation have been found which result in tissue fibrosis as well as loss of muscle fibers, decreased fiber size and necrosis. The late effects of tissue fibrosis can have a negative impact on swallow functioning, with impairment in tongue and tongue base strength and range of motion, pharyngeal constrictor motion, reduced laryngeal motion for airway protection and upper esophageal sphincter opening and reduced bolus clearance through the pharynx. A reduction in both speed, strength and degree of structural movement within the oral cavity and pharynx can impact on bolus flow and clearance. Altered head and neck anatomy following surgery can result in swallowing deficits within the oral and pharyngeal phases of swallowing, depending on the specific structures resected. However, across treatment type, patients often exhibit impairment in bolus propulsion and clearance through the oral cavity and pharynx, as well as impairment in airway protection due to reduced glottic and supraglottic closure. Any of these deficits can result in bolus mis-direction and aspiration before, during or after the swallow.




Introduction


The incidence of head and neck cancer (HNC) has increased significantly over the past decade. According to the American Cancer Society, in 2012 an estimated 92,860 new cancer cases involved the oral cavity and pharynx, tongue, mouth, pharynx, other oral cavity, and larynx ( Fig. 1 ).




Fig. 1


Estimated new number of head & neck cancer cases by location in 2012 versus 2005 according to the American Cancer Society.

( Data from American Cancer Society. Cancer Facts & Figures 2012. Atlanta (GA): American Cancer Society; 2012. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf .)


The steady increase in incidence rates of oropharyngeal cancer over the past several decades has been attributed to the growing number of human papillomavirus (HPV)–related cancers. More than 90% of HPV-positive oropharyngeal cancers are associated with 2 oncogenic high-risk HPV types: HPV 16 and HPV 18. Subtype HPV 16 has been associated with 85% to 90% of all HPV-positive oropharyngeal cancers. Persistent HPV infection of the oral cavity may lead to genetic damage and altered immune function, promoting progression to cancer; specifically squamous cell carcinoma of the tonsil and base of tongue.


HPV status has been strongly associated with therapeutic response and overall survival in patients with oropharyngeal cancer. In general, survival rates for HPV-related oropharyngeal cancer are higher than those for HPV-unrelated oropharyngeal cancers, with 2-year survival rates ranging from 80% to 95% versus 50% to 65%, respectively. However, treatment for HPV-related and HPV-unrelated oropharyngeal cancers are currently commensurate. To date, little research has been conducted to determine if functional outcomes, including swallowing physiology, are similar among these heterogeneous groups.


Surgery, chemoradiotherapy or a combination of treatment can alter both the anatomy and tissue characteristics of those structures and muscles involved in swallowing. Radiotherapy can affect muscles, nerves, and the vascular system. Injury to the neuromuscular junctures and radiation-induced neuropathy can result in impairment in nerve conduction, muscle fiber atrophy, necrosis, and impairment in muscle contraction with an increase in connective tissue. Vascular changes following irradiation have been found which result in tissue fibrosis as well as loss of muscle fibers, decreased fiber size and necrosis. The late effects of tissue fibrosis can have a negative impact on swallow functioning, with impairment in tongue and tongue base strength and range of motion, pharyngeal constrictor motion, reduced laryngeal motion for airway protection and upper esophageal sphincter opening and reduced bolus clearance through the pharynx. A reduction in both speed, strength and degree of structural movement within the oral cavity and pharynx can impact on bolus flow and clearance. Altered head and neck anatomy following surgery can result in swallowing deficits within the oral and pharyngeal phases of swallowing, depending on the specific structures resected. However, across treatment type, patients often exhibit impairment in bolus propulsion and clearance through the oral cavity and pharynx, as well as impairment in airway protection due to reduced glottic and supraglottic closure. Any of these deficits can result in bolus mis-direction and aspiration before, during or after the swallow.




Radiation therapy


Improvements in radiation therapy, including intensity-modulated radiotherapy (IMRT), and the addition of chemotherapy agents have dramatically shifted the care for HNC. The use of radiation therapy (XRT) ± chemotherapy, either as an adjunct to surgery or as a definitive treatment, has allowed for the development of organ-sparing treatments without a decrease in overall survival. However, these treatment modalities can have adverse effects on overall function and quality of life, causing side effects such as radiation dermatitis, pain, mucositis, soft tissue edema, weight loss, xerostomia, loss of taste, hoarseness, fibrosis, trismus, and dysphagia. Dysphagia is often the most problematic short-term and long-term effect seen in this population. Long-term dysphagia often results in critical consequences, including aspiration and dietary inadequacies, leading to malnutrition and its associated adverse effects.


The reported incidence rates of dysphagia after XRT and chemotherapy are highly variable. Nguyen and colleagues reported an average incidence of dysphagia of 50% after chemotherapy for advanced-stage HNC. Others have reported as many as two-thirds of all patients with HNC are left with permanent swallowing problems. These problems directly impact an individual’s nutritional status, hydration, and pulmonary health in addition to having a major impact on quality of life.


Characteristics of dysphagia secondary to XRT or chemotherapy depend primarily on tumor size and the presence or absence of metastatic neck disease. These features greatly impact the radiation field and dose required for definitive treatment. Common physiologic deficits and their impact on bolus transport are outlined in Table 1 . Impaired base of tongue retraction and reduced hyolaryngeal elevation have been identified as 2 of the most salient features of dysphagia after XRT ( Fig. 2 ). Lingual strength in patients with oral and oropharyngeal cancer treated with primary chemotherapy has been found to be lower than in that seen in healthy controls. Lingual strength has also been found to correlate with aspiration.



Table 1

Common characteristics of dysphagia after radiation therapy ± chemotherapy
















Oral Impairment
Trismus Inability to open mouth to accept oral intake
Impaired chewing
Dry mouth Reduced range of motion of oral structures
Impaired oral transit
Difficulty breaking down food without saliva enzymes
Increased risk of caries
Lingual weakness Impaired bolus formation
Impaired anteroposterior transport and bolus clearance leading to oral residue
Lateral sulci residue



















Pharyngeal Impairment
Decreased base of tongue retraction Impaired bolus propulsion
Pharyngeal residue
Increased number of swallows
Reduced laryngeal elevation/excursion Impaired epiglottic inversion
Impaired airway protection
Penetration/aspiration
Reduced opening of the cricopharyngeal segment resulting in pharyngeal residue
Impaired contraction of the pharyngeal constrictors Impaired bolus transport and clearance through the pharynx
Reduced opening of the cricopharyngeal segment resulting in pharyngeal residue
Stenosis of the cricopharyngeal segment Reduced or absent bolus clearance resulting in pharyngeal residue



Fig. 2


Postchemotherapy deficits. ( A ) Arrows shows the reduced base of tongue retraction. ( B ) Arrow shows the reduced laryngeal elevation and airway closure.


Radiation treatment for HNC has shifted primarily to IMRT over the past decade. This shift has allowed for the delivery of nonuniform radiation intensities to various structures, thus protecting structures important for swallowing when possible. A recent study has compared physiologic measures of swallow functioning after IMRT versus conventional radiotherapy. Results indicate that individuals treated with IMRT maintain better swallow function with regard to timing, efficiency, and airway protection compared with individuals treated with conventional radiotherapy.


Undoubtedly, given the incidence of dysphagia in the population and the negative impact on swallow function and safety, the potential role of intervention during treatment is increasingly recognized as a means of maintaining oropharyngeal function. Although early treatment is recommended, it has not been operationally defined at this time. Few studies have looked at prophylactic swallowing intervention by way of muscle strengthening. However, only 2 of these studies were randomized controlled trials, with only 1 including a control group. All studies differed in outcome measures. These studies are outlined in Table 2 .



Table 2

Studies assessing prophylactic swallowing exercises for patient undergoing definitive radiation therapy for head and neck cancer








































Author Outcome Measures Therapy Exercises Onset of Exercises Results
Van der Molen et al, 2011 a


  • Pretreatment and 10 wk posttreatment:




    • VFSS



    • BMI



    • FOIS score



    • Weight changes



    • Pain scale



    • Study-specific questionnaire





  • Jaw exercises



  • Gargle



  • Masako



  • Super-supraglottic swallow

vs


  • TheraBite stretch



  • TheraBite swallow

2 wk before chemoradiation Significant decrease in mouth opening, weight loss, and oral intake for both groups
No significant difference between the pretreatment and posttreatment PAS scores
Carnaby-Mann et al, 2012 a


  • Pretreatment, after treatment, and 6 mo posttreatment:




    • Muscle size and composition (determined by T2-weighted MRI)



    • Functional swallowing ability



    • Dietary intake



    • Chemosensory function



    • Salivation



    • Nutritional status



    • Occurrence of dysphagia-related complications





  • Supervised feeding and safe swallowing precautions/education

vs


  • Buccal extension maneuver



  • Dietary modification

vs


  • Falsetto



  • Tongue press



  • Hard swallow



  • Jaw resistance/strengthening using the Therabite Jaw Motion Rehabilitation System



  • Dietary modification

At the start of chemoradiation Significant differences were seen in superior muscle maintenance and functional swallowing ability
Kulbersh et al, 2006


  • 9 mo posttreatment (range, 6–12 mo):




    • MDADI


Falsetto
Masako
Mendelsohn
Shaker
Lingual resistance (all participants)
2 wk before radiation ± chemotherapy Improved QOL measures: physical, emotional, global
No improved QOL in the functional domain
Carroll et al, 2008


  • 3 mo posttreatment:




    • VFSS




  • 12 mo posttreatment:




    • PEG status





  • Effortful swallow



  • Masako



  • Mendelsohn



  • Shaker



  • Lingual resistance (treatment group)

vs


  • Unspecified swallowing exercises (control)




  • 2 wk before chemoradiation

vs


  • Postchemoradiation

Significant differences in epiglottic inversion and tongue position during swallow
No difference in PEG removal
Kotz et al, 2012


  • Baseline, immediately after treatment, and at 3, 6, 9, and 12 mo posttreatment:




    • FOIS score



    • PSS-HN score





  • No treatment

vs


  • Effortful swallow



  • 2 tongue base retraction exercises



  • Super-supraglottic swallow technique



  • Mendelsohn maneuver

At the start of chemoradiation FOIS and PSS-HN: no significant difference immediately after CRT or at 9 or 12 mo after CRT
Significant differences at 3 and 6 mo after CRT

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Apr 1, 2017 | Posted by in OTOLARYNGOLOGY | Comments Off on Special Groups

Full access? Get Clinical Tree

Get Clinical Tree app for offline access